CURI: the cash flow

MyFinsight

For the year ending 2025-12-31, CURI had $10,427K increase in cash & cash equivalents over the period. $12,955K in free cash flow.

Cash Flow	2025-12-31
Net loss	-6,427
Change in fair value of warrant liability	88
Additions to content assets	-13,944
Change in content liabilities	80
Amortization of content assets	14,511
Depreciation and amortization expenses	164
Amortization of premiums and accretion of discounts associated with investments in debt securities, net	-517
Stock-based compensation	14,366
Equity method investment loss	180
Other non-cash items	468
Accounts receivable	2,790
Other assets	194
Accounts payable	3,795
Accrued expenses and other liabilities	6,070
Deferred revenue	-2,617
Net cash provided by operating activities	13,057
Purchases of property and equipment	102
Sales of investments in debt securities	5,001
Maturities of investments in debt securities	30,550
Purchases of investments in debt securities	12,301
Net cash provided by (used in) investing activities	23,148
Repurchases of common stock	0
Dividends paid	22,010
Payments related to tax withholding	3,768
Net cash used in financing activities	-25,778
Net increase (decrease) in cash, cash equivalents and restricted cash	10,427
Cash, cash equivalents and restricted cash, beginning of period	7,951
Cash, cash equivalents and restricted cash, end of period	18,378

Unit: Thousand (K) dollars (except for numbers of shares and EPS).